Printer Friendly

FDA Approves EFFEXOR(R) XR (venlafaxine HCl) - The First SNRI - For Treatment of Social Anxiety Disorder; Video Available Soon At: http://www.prnewswire.com/broadcast/10104/10104_consumer.html.

NEW YORK -- NEW YORK, Feb. 11 /PRNewswire/ -- Social anxiety disorder (SAD), or social phobia, is the third most common psychiatric disorder in the United States, affecting approximately 10 million Americans. It is a debilitating illness marked by overwhelming and disabling fear of scrutiny, embarrassment, or humiliation in social situations, which are often avoided or endured with dread. Despite its impact and prevalence, SAD is widely undertreated.

Until recently, there have been limited therapies available to treat the symptoms of social phobia. However, the FDA has approved the antidepressant EFFEXOR(R) XR, the first serotonin-norepinephrine reuptake inhibitor (SNRI) for this condition. EFFEXOR XR has been used effectively for years to treat people suffering from depression and generalized anxiety disorder.

EFFEXOR XR works differently than the other FDA-approved treatments for SAD, selective serotonin reuptake inhibitors (SSRI). As an SNRI, EFFEXOR XR works on both serotonin and norepinephrine -- chemicals thought to affect mood, motivation, and energy, and thought to be deficient in individuals suffering from depression and anxiety disorders. The SSRI antidepressants increase the levels of only serotonin.

For more information about EFFEXOR XR, visit the web site at http://www.effexorxr.com/.
 SOUNDBITES:
 * Jeffrey E. Kelsey, M.D., Ph.D., Medical Director, Georgia Institute of
 Mood and Anxiety Disorders
 * Patricia Acker, Social Anxiety Disorder Patient
 Video Provided By: Wyeth


CONTACT: FOR TECHNICAL INFORMATION OR HARD COPY REQUESTS PLEASE CALL: MARIA MCCARTHY (212) 727-1742

Web site: http://www.effexorxr.com/
COPYRIGHT 2003 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2003 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Feb 12, 2003
Words:237
Previous Article:Glancy & Binkow LLP Commences Class Action Lawsuit and Seeks To Recover Losses for Investors Who Purchased Sawtek, Inc.
Next Article:Apartment Investment and Management Company Announces Fourth Quarter and Full Year 2002 Results; Completed $218 Million in Property Sales in the...


Related Articles
Studies Show That the Antidepressant Effexor(R) XR Also Provides Effective Relief of Anxiety Symptoms
American Home Products Corporation/.
EFFEXOR(R) XR Remains First and Only SNRI Antidepressant for Long-Term Treatment of Generalized Anxiety Disorder (GAD).
Comprehensive Pooled Analysis of Antidepressant Studies Demonstrated Significant Efficacy of EFFEXOR (Venlafaxine HCL)/EFFEXOR XR (Venlafaxine HCL);...
Landmark Antidepressant Analysis Demonstrated Significant Efficacy of EFFEXOR(R)/EFFEXOR XR; EFFEXOR/EFFEXOR XR Provided Higher Remission and...
EFFEXOR(R) XR Approved for the Treatment of Social Anxiety Disorder; First SNRI Proven Effective in Treatment of this Disabling Condition.
Wyeth's EFFEXOR(R) XR Significantly Relieves Physical and Emotional Symptoms of Depression and Generalized Anxiety Disorder.
EFFEXOR XR Approved for the Treatment of Panic Disorder.

Terms of use | Copyright © 2018 Farlex, Inc. | Feedback | For webmasters